Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2408585 | Vaccine | 2005 | 7 Pages |
Abstract
In a phase I/II dose escalation study, varying volumes (0.1 ml, 0.5 ml, 1.0 ml and 2.0 ml) of 7-valent pneumococcal conjugate vaccine (PCV) (Prevnar®) or 0.5 ml of 23-valent pneumococcal polysaccharide vaccine (PPV) were administered to 220 adults 70 through 79 years of age previously vaccinated with 0.5 ml PPV at age 65 years or above and at least 5 years previously. Fever was uncommon and did not vary by study group. The rate of local reactions increased with higher volumes of PCV and the rate following 2.0 ml of PCV was comparable to that following 0.5 ml PPV.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Lisa A. Jackson, Kathleen M. Neuzil, Cynthia G. Whitney, Patty Starkovich, Maya Dunstan, Onchee Yu, Jennifer C. Nelson, Daniel R. Feikin, David K. Shay, James Baggs, Barb Carste, Moon H. Nahm, George Carlone,